JP2015504921A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015504921A5 JP2015504921A5 JP2014554868A JP2014554868A JP2015504921A5 JP 2015504921 A5 JP2015504921 A5 JP 2015504921A5 JP 2014554868 A JP2014554868 A JP 2014554868A JP 2014554868 A JP2014554868 A JP 2014554868A JP 2015504921 A5 JP2015504921 A5 JP 2015504921A5
- Authority
- JP
- Japan
- Prior art keywords
- hetre
- use according
- medicament
- microbial infection
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 2
- 125000005907 alkyl ester group Chemical group 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 239000011780 sodium chloride Substances 0.000 claims description 2
- FPMGOQWJNUZGTC-KPQBNAFWSA-N (2E,4E,6E)-15-hydroxyicosa-2,4,6-trienoic acid Chemical compound CCCCCC(O)CCCCCCC\C=C\C=C\C=C\C(O)=O FPMGOQWJNUZGTC-KPQBNAFWSA-N 0.000 claims 20
- 239000003814 drug Substances 0.000 claims 8
- 201000009910 diseases by infectious agent Diseases 0.000 claims 5
- 230000000813 microbial Effects 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 200000000019 wound Diseases 0.000 claims 3
- 229960000282 Metronidazole Drugs 0.000 claims 2
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 230000037390 scarring Effects 0.000 claims 2
- GSDSWSVVBLHKDQ-JTQLQIEISA-N (2S)-7-fluoro-2-methyl-6-(4-methylpiperazin-1-yl)-10-oxo-4-oxa-1-azatricyclo[7.3.1.0^{5,13}]trideca-5(13),6,8,11-tetraene-11-carboxylic acid Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 claims 1
- JFPVXVDWJQMJEE-IZRZKJBUSA-N (6R,7R)-3-[(carbamoyloxy)methyl]-7-[(2Z)-2-(furan-2-yl)-2-(methoxyimino)acetamido]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 JFPVXVDWJQMJEE-IZRZKJBUSA-N 0.000 claims 1
- ORFOPKXBNMVMKC-DWVKKRMSSA-O (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2-carboxypropan-2-yloxyimino)acetyl]amino]-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 ORFOPKXBNMVMKC-DWVKKRMSSA-O 0.000 claims 1
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-oxazolidone Chemical compound O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 claims 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N Ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 claims 1
- 229940064005 Antibiotic throat preparations Drugs 0.000 claims 1
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 claims 1
- 229940042052 Antibiotics for systemic use Drugs 0.000 claims 1
- 229940042786 Antitubercular Antibiotics Drugs 0.000 claims 1
- 240000000940 Araucaria angustifolia Species 0.000 claims 1
- 206010060945 Bacterial infection Diseases 0.000 claims 1
- 241000222122 Candida albicans Species 0.000 claims 1
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N Cefalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 claims 1
- XIURVHNZVLADCM-IUODEOHRSA-N Cefalotin Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C(O)=O)C(=O)CC1=CC=CS1 XIURVHNZVLADCM-IUODEOHRSA-N 0.000 claims 1
- GPRBEKHLDVQUJE-VINNURBNSA-N Cefotaxime Chemical compound N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C(O)=O)=O)C(=O)/C(=N/OC)C1=CSC(N)=N1 GPRBEKHLDVQUJE-VINNURBNSA-N 0.000 claims 1
- 229960004261 Cefotaxime Drugs 0.000 claims 1
- 229960000484 Ceftazidime Drugs 0.000 claims 1
- 229960001668 Cefuroxime Drugs 0.000 claims 1
- 229940106164 Cephalexin Drugs 0.000 claims 1
- 229940106195 Cephalothin Drugs 0.000 claims 1
- MYSWGUAQZAJSOK-UHFFFAOYSA-N Ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 claims 1
- 241000069665 Crenosoma striatum Species 0.000 claims 1
- 229960003722 Doxycycline Drugs 0.000 claims 1
- XQTWDDCIUJNLTR-CVHRZJFOSA-N Doxycycline Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 claims 1
- 241000588724 Escherichia coli Species 0.000 claims 1
- 241000495778 Escherichia faecalis Species 0.000 claims 1
- 206010017533 Fungal infection Diseases 0.000 claims 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 claims 1
- 108010015899 Glycopeptides Proteins 0.000 claims 1
- 102000002068 Glycopeptides Human genes 0.000 claims 1
- 229940093922 Gynecological Antibiotics Drugs 0.000 claims 1
- 229960002182 IMIPENEM Drugs 0.000 claims 1
- ZSKVGTPCRGIANV-ZXFLCMHBSA-N IMIPENEM Chemical compound C1C(SCC\N=C\N)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 ZSKVGTPCRGIANV-ZXFLCMHBSA-N 0.000 claims 1
- DMJNNHOOLUXYBV-PQTSNVLCSA-N Meropenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](C(=O)N(C)C)C1 DMJNNHOOLUXYBV-PQTSNVLCSA-N 0.000 claims 1
- PGBHMTALBVVCIT-VCIWKGPPSA-N Neomycin Chemical group N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO PGBHMTALBVVCIT-VCIWKGPPSA-N 0.000 claims 1
- 229940053050 Neomycin Sulfate Drugs 0.000 claims 1
- 229940049954 Penicillin Drugs 0.000 claims 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims 1
- 108010093965 Polymyxin B Proteins 0.000 claims 1
- 241000191963 Staphylococcus epidermidis Species 0.000 claims 1
- 229960002180 Tetracycline Drugs 0.000 claims 1
- 239000004098 Tetracycline Substances 0.000 claims 1
- OFVLGDICTFRJMM-WESIUVDSSA-N Tetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O OFVLGDICTFRJMM-WESIUVDSSA-N 0.000 claims 1
- 229960000707 Tobramycin Drugs 0.000 claims 1
- NLVFBUXFDBBNBW-PBSUHMDJSA-N Tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 claims 1
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 claims 1
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 claims 1
- IEDVJHCEMCRBQM-UHFFFAOYSA-N Trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 claims 1
- 229960001082 Trimethoprim Drugs 0.000 claims 1
- 229960003165 Vancomycin Drugs 0.000 claims 1
- 108010059993 Vancomycin Proteins 0.000 claims 1
- OJYLAHXKWMRDGS-UHFFFAOYSA-N Zingerone Chemical compound COC1=CC(CCC(C)=O)=CC=C1O OJYLAHXKWMRDGS-UHFFFAOYSA-N 0.000 claims 1
- 229960003022 amoxicillin Drugs 0.000 claims 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 claims 1
- 229960000723 ampicillin Drugs 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 229960000626 benzylpenicillin Drugs 0.000 claims 1
- 230000003115 biocidal Effects 0.000 claims 1
- YZBQHRLRFGPBSL-RXMQYKEDSA-N carbapenem Chemical compound C1C=CN2C(=O)C[C@H]21 YZBQHRLRFGPBSL-RXMQYKEDSA-N 0.000 claims 1
- 229960003525 cefalexin Drugs 0.000 claims 1
- 229960000603 cefalotin Drugs 0.000 claims 1
- 229960003405 ciprofloxacin Drugs 0.000 claims 1
- -1 fluoroquinolone Chemical compound 0.000 claims 1
- 229960002518 gentamicin Drugs 0.000 claims 1
- 230000035876 healing Effects 0.000 claims 1
- 229940079866 intestinal antibiotics Drugs 0.000 claims 1
- 229960003376 levofloxacin Drugs 0.000 claims 1
- 229960002260 meropenem Drugs 0.000 claims 1
- 229960004927 neomycin Drugs 0.000 claims 1
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 claims 1
- 229960005266 polymyxin B Drugs 0.000 claims 1
- 229920000024 polymyxin B Polymers 0.000 claims 1
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2(1H)-one Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 claims 1
- 229960005404 sulfamethoxazole Drugs 0.000 claims 1
- JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 claims 1
- 235000019364 tetracycline Nutrition 0.000 claims 1
- 230000001225 therapeutic Effects 0.000 claims 1
- 229960003500 triclosan Drugs 0.000 claims 1
- MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 claims 1
- 230000029663 wound healing Effects 0.000 claims 1
- WLKCSMCLEKGITB-UHFFFAOYSA-N 15-hydroxyicosa-5,8,11,13,17-pentaenoic acid Chemical compound CCC=CCC(O)C=CC=CCC=CCC=CCCCC(O)=O WLKCSMCLEKGITB-UHFFFAOYSA-N 0.000 description 2
- WLKCSMCLEKGITB-XWJJKCKWSA-N 15-HEPE Chemical compound CC\C=C/CC(O)\C=C\C=C/C\C=C/C\C=C/CCCC(O)=O WLKCSMCLEKGITB-XWJJKCKWSA-N 0.000 description 1
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
Description
１５−ヒドロキシ−エイコサ−５，８，１１，１３，１７−ペンタエン酸（「１５−ＯＨＥＰＡ」又は「１５−ＨＥＰＥ」）はＥＰＡの誘導体である。本明細書で使用される場合、「１５−ＯＨＥＰＡ」という用語は、遊離酸形態の１５−ＯＨＥＰＡ（例えば、１５−ヒドロキシ−エイコサ−５，８，１１，１３，１７−ペンタエン酸）および／または医薬的に許容可能なそれらのエステル、誘導体、複合物もしくは塩または前述の何れかの混合物を指す。一部の実施形態において、１５−ＯＨＥＰＡは、Ｃ１−４アルキルエステルの形態、例えばメチルエステルまたはエチルエステルなどの形態である。
Claims (20)
- それを必要とする対象における、微生物感染の処置または予防するための医薬品の製造における１５−ヒドロキシエイコサトリエン酸（「１５−ＨＥＴｒＥ」）の使用。
- 前記医薬品が対象に局所的に適用される、請求項１に記載の使用。
- 前記医薬品が対象の創傷に局所的に適用される、請求項２に記載の使用。
- 前記微生物感染が細菌感染である、請求項１〜３のいずれかに記載の使用。
- 前記微生物感染が真菌感染である、請求項１〜４のいずれかに記載の使用。
- 前記医薬品が、微生物感染を処置するかまたは予防するのに有効な量での投与のためのものである、請求項１〜５のいずれかに記載の使用。
- 前記医薬品が、約０．１重量％〜約２０重量％の１５−ＨＥＴｒＥおよび１以上の賦形剤を含む、請求項１〜６のいずれかに記載の使用。
- 前記１５−ＨＥＴｒＥが遊離酸形態である、請求項１〜７のいずれかに記載の使用。
- 前記１５−ＨＥＴｒＥが、１５−ＨＥＴｒＥの医薬的に許容可能なエステル、コンジュゲートまたは塩である、請求項１〜８のいずれかに記載の使用。
- 前記１５−ＨＥＴｒＥが１５−ＨＥＴｒＥのアルキルエステルである、請求項１〜９のいずれかに記載の使用。
- 前記医薬品が、硫酸ネオマイシン、ポリミキシンＢ、亜鉛バシトラシン、アンピシリン、アモキシシリン、イミペネム、メロペネム、カルバペネム、セファレキシン、セファロチン、セファロジン、セフロキシム、セフォタキシム、セフタジジム、フルオロキノロン、オキサゾリジノン、リンコサミド、メトロニダゾール、クリンダマイシン、エリスロマイシン、キノロン抗生物質、レボフロキサシン、シプロフロキサシン、ペニシリン、グリコペプチド、バンコマイシン、アミノグリコシド、ネオマイシン、ゲンタマイシン、トブラマイシン、トリメトプリム／スルファメトキサゾール、ドキシサイクリン、トリクロサン、メトロニダゾール、モノサイクリンおよびテトラサイクリンならびにこれらの組み合わせから選択されるさらなる活性剤をさらに含む、請求項１〜１０のいずれかに記載の使用。
- 前記さらなる活性剤が、該さらなる活性剤に対して一般に認識される治療量未満の量で存在する、請求項１〜１１のいずれかに記載の使用。
- 前記１５−ＨＥＴｒＥが脱臭されている、請求項１〜１２のいずれかに記載の使用。
- 前記医薬品が、Ｐ．エアロギノーサ（Ｐ．ａｅｒｏｇｉｎｏｓａ）、大腸菌（Ｅ．ｃｏｌｉ）、Ｋ．ニューモニエ（Ｋ．ｐｎｅｕｍｏｎｉａｅ）、Ｓ．アウレウス（Ｓ．ａｕｒｅｕｓ）、Ｅ．フェカリス（Ｅ．ｆａｅｃａｌｉｓ）、Ｓ．エピデルミデス（Ｓ．ｅｐｉｄｅｒｍｉｄｉｓ）、Ｃ．ストリアタム（Ｃ．ｓｔｒｉａｔｕｍ）、Ａ．ブラジリエンシス（Ａ．ｂｒａｓｉｌｉｅｎｓｉｓ）、Ｃ．アルビカンス（Ｃ．ａｌｂｉｃａｎｓ）またはそれらのいずれかの組み合わせの増殖を阻害する、請求項１〜１３のいずれかに記載の使用。
- 瘢痕化を最小限に抑えるかまたは予防するための医薬品の製造における１５−ヒドロキシエイコサトリエン酸（「１５−ＨＥＴｒＥ」）の使用であって、該医薬品が対象の創傷への投与のためのものである、前記使用。
- 微生物感染の処置または予防における使用のための、１５−ヒドロキシエイコサトリエン酸（１５−ＨＥＴｒＥ）を含む、医薬組成物。
- 瘢痕化を最小限に抑えるかまたは予防するための、１５−ヒドロキシエイコサトリエン酸（１５−ＨＥＴｒＥ）を含む、医薬組成物。
- 創傷治癒における使用のための、１５−ヒドロキシエイコサトリエン酸（１５−ＨＥＴｒＥ）を含む、医薬組成物。
- 約０．１重量％〜約２０重量％の１５−ＨＥＴｒＥおよび１以上の賦形剤を含む、請求項１６〜１８のいずれか１項に記載の医薬組成物。
- 創傷を治癒するための医薬品の製造における、１５−ヒドロキシエイコサトリエン酸（「１５−ＨＥＴｒＥ」）の使用。
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261591036P | 2012-01-26 | 2012-01-26 | |
| US61/591,036 | 2012-01-26 | ||
| US13/478,990 | 2012-05-23 | ||
| US13/478,990 US20120264705A1 (en) | 2012-01-26 | 2012-05-23 | Antimicrobial compositions comprising 15-hetre and methods of use thereof |
| PCT/US2013/023201 WO2013112876A1 (en) | 2012-01-26 | 2013-01-25 | Antimicrobial compositions comprising dgla, 15-ohepa and/or 15-hetre and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017217054A Division JP2018065818A (ja) | 2012-01-26 | 2017-11-10 | Ｄｇｌａ、１５−ｏｈｅｐａおよび／または１５−ｈｅｔｒｅを含む抗菌組成物およびそれらの使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015504921A JP2015504921A (ja) | 2015-02-16 |
| JP2015504921A5 true JP2015504921A5 (ja) | 2016-03-10 |
| JP6557009B2 JP6557009B2 (ja) | 2019-08-07 |
Family
ID=47006834
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014554868A Expired - Fee Related JP6557009B2 (ja) | 2012-01-26 | 2013-01-25 | Ｄｇｌａ、１５−ｏｈｅｐａおよび／または１５−ｈｅｔｒｅを含む抗菌組成物およびそれらの使用方法 |
| JP2017217054A Pending JP2018065818A (ja) | 2012-01-26 | 2017-11-10 | Ｄｇｌａ、１５−ｏｈｅｐａおよび／または１５−ｈｅｔｒｅを含む抗菌組成物およびそれらの使用方法 |
| JP2019176350A Pending JP2020023513A (ja) | 2012-01-26 | 2019-09-27 | Ｄｇｌａ、１５−ｏｈｅｐａおよび／または１５−ｈｅｔｒｅを含む抗菌組成物およびそれらの使用方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017217054A Pending JP2018065818A (ja) | 2012-01-26 | 2017-11-10 | Ｄｇｌａ、１５−ｏｈｅｐａおよび／または１５−ｈｅｔｒｅを含む抗菌組成物およびそれらの使用方法 |
| JP2019176350A Pending JP2020023513A (ja) | 2012-01-26 | 2019-09-27 | Ｄｇｌａ、１５−ｏｈｅｐａおよび／または１５−ｈｅｔｒｅを含む抗菌組成物およびそれらの使用方法 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20120264705A1 (ja) |
| EP (1) | EP2806868A4 (ja) |
| JP (3) | JP6557009B2 (ja) |
| KR (1) | KR20140117379A (ja) |
| CN (1) | CN104114166A (ja) |
| AU (1) | AU2013211982A1 (ja) |
| BR (1) | BR112014018421A8 (ja) |
| CA (1) | CA2857046A1 (ja) |
| HK (1) | HK1198921A1 (ja) |
| IL (1) | IL232777A0 (ja) |
| MX (1) | MX2014006947A (ja) |
| PH (1) | PH12014501693A1 (ja) |
| RU (1) | RU2014134720A (ja) |
| SG (1) | SG11201404088TA (ja) |
| WO (1) | WO2013112876A1 (ja) |
| ZA (1) | ZA201403948B (ja) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0907413D0 (en) | 2009-04-29 | 2009-06-10 | Equateq Ltd | Novel methods |
| US8293790B2 (en) | 2011-10-19 | 2012-10-23 | Dignity Sciences Limited | Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof |
| US9855236B2 (en) | 2011-10-19 | 2018-01-02 | Ds Biopharma Limited | Pharmaceutical compositions comprising DGLA and/or 15-HETrE and methods of use thereof |
| EP2768496A1 (en) * | 2011-10-19 | 2014-08-27 | Dignity Sciences Limited | Pharmaceutical compositions comprising dgla and/or 15-hetre and methods of use thereof |
| GB201301626D0 (en) * | 2013-01-30 | 2013-03-13 | Dignity Sciences Ltd | Composition comprising 15-OHEPA and methods of using the same |
| GB201307082D0 (en) * | 2013-04-19 | 2013-05-29 | Dignity Sciences Ltd | Pharmaceutical composition comprising 15-HETrE and methods of using the same |
| US20150080329A1 (en) * | 2013-09-19 | 2015-03-19 | Dignity Sciences Limited | Pharmaceutical compositions comprising dha, epa, and/or gla and an antibiotic agent and methods of use thereof |
| CN105899485B (zh) | 2013-11-15 | 2018-10-19 | 尊严科学有限公司 | 多不饱和羟基脂肪酸的药学上可接受的盐 |
| MX2016008953A (es) * | 2014-01-10 | 2017-02-02 | Dignity Sciences Ltd | Composiciones farmaceuticas que comprenden i5-hidroxi-eicosa- 5,8,11,13,17-pentaenoico ( 15-hepe ) y metodos para tratar el asma y trastornos pulmonares que usan las mismas. |
| US9682055B2 (en) | 2014-06-04 | 2017-06-20 | Dignity Sciences Limted | Pharmaceutical compositions comprising DGLA and use of same |
| LT6177B (lt) | 2014-10-10 | 2015-07-27 | Uab "Biocentras" | Fermentų kompleksų išskyrimas iš steptomyces gougerotii 101, daugiafermentinių biopreparatų ruošimas bei taikymas |
| MA41120A (fr) | 2014-12-02 | 2017-10-10 | Afimmune Ltd | Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci |
| CN107405324A (zh) * | 2015-01-16 | 2017-11-28 | 艾菲穆恩有限公司 | 包含15‑hepe的组合物和其使用方法 |
| EP3861995A1 (en) | 2015-07-21 | 2021-08-11 | Affimune Limited | Compositions comprising 15-hepe for use in treating or preventing neurologic disease |
| US9855238B2 (en) * | 2015-12-18 | 2018-01-02 | Afimmune Limited | Compositions comprising 15-HEPE and methods of using the same |
| WO2019042796A1 (en) | 2017-08-30 | 2019-03-07 | Unilever N.V. | COMPOSITION OF BODY CARE |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4344930A (en) * | 1975-10-30 | 1982-08-17 | Colgate-Palmolive Company | Skin care sponge |
| US5789441A (en) * | 1996-02-15 | 1998-08-04 | Virocell Inc. | Leukotriene B4 as an antiviral and anti-neoplastic agent |
| JP4926310B2 (ja) * | 1996-02-15 | 2012-05-09 | エルテーベー４・スウェーデン・アクチェボラーグ | 抗ウイルス薬および抗腫瘍薬としてのロイコトリエンｂ４またはその類似体の使用 |
| US6190645B1 (en) * | 1999-07-15 | 2001-02-20 | Playtex Products, Inc. | Sunscreen for the scalp hair and hair |
| US20030073930A1 (en) * | 2001-10-17 | 2003-04-17 | Morrissey Gerald R. | Methods and device for preventing or healing injured nipples or areolas in mammalian females or for obtaining samples from nipples in mammalian females |
| US20030105445A1 (en) * | 2001-11-30 | 2003-06-05 | Kimberly-Clark Worldwide, Inc. | Breast pad assembly containing a skin benefit ingredient |
| WO2005102309A2 (en) * | 2004-04-26 | 2005-11-03 | Ltb4 Sweden Ab | In vivo release of endogenous anti-microbial mediators by leukotriene b4 (ltb4) administration |
| US20120115923A1 (en) * | 2005-12-30 | 2012-05-10 | Intradigm Corporation | Sirna Compositions Promoting Scar-Free Wound Healing of Skin and Methods for Wound Treatment |
| RU2443122C2 (ru) * | 2006-11-23 | 2012-02-27 | Карджилл, Инкорпорейтед | Натуральный эквивалент химически модифицированного крахмала |
| US20110038917A1 (en) * | 2007-05-08 | 2011-02-17 | Rq Bioscience, Inc. | Therapeutic compositions and methods for treating gram-negative bacterial infections |
| EP2159732A1 (en) * | 2008-08-21 | 2010-03-03 | Thomson Licensing | Method and device for code obfuscation |
| GB0907413D0 (en) * | 2009-04-29 | 2009-06-10 | Equateq Ltd | Novel methods |
| US8399226B2 (en) * | 2009-06-16 | 2013-03-19 | E I Du Pont De Nemours And Company | High eicosapentaenoic acid oils from improved optimized strains of Yarrowia lipolytica |
| US8293790B2 (en) * | 2011-10-19 | 2012-10-23 | Dignity Sciences Limited | Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof |
-
2012
- 2012-05-23 US US13/478,990 patent/US20120264705A1/en not_active Abandoned
-
2013
- 2013-01-25 JP JP2014554868A patent/JP6557009B2/ja not_active Expired - Fee Related
- 2013-01-25 SG SG11201404088TA patent/SG11201404088TA/en unknown
- 2013-01-25 CN CN201380006224.7A patent/CN104114166A/zh active Pending
- 2013-01-25 EP EP13741302.7A patent/EP2806868A4/en not_active Withdrawn
- 2013-01-25 WO PCT/US2013/023201 patent/WO2013112876A1/en active Application Filing
- 2013-01-25 AU AU2013211982A patent/AU2013211982A1/en not_active Abandoned
- 2013-01-25 KR KR1020147018192A patent/KR20140117379A/ko active IP Right Grant
- 2013-01-25 BR BR112014018421A patent/BR112014018421A8/pt not_active Application Discontinuation
- 2013-01-25 MX MX2014006947A patent/MX2014006947A/es unknown
- 2013-01-25 RU RU2014134720A patent/RU2014134720A/ru not_active Application Discontinuation
- 2013-01-25 CA CA2857046A patent/CA2857046A1/en not_active Abandoned
-
2014
- 2014-02-21 US US14/186,200 patent/US20140171358A1/en not_active Abandoned
- 2014-05-25 IL IL232777A patent/IL232777A0/en unknown
- 2014-05-29 ZA ZA2014/03948A patent/ZA201403948B/en unknown
- 2014-07-25 PH PH12014501693A patent/PH12014501693A1/en unknown
- 2014-12-10 HK HK14112445.0A patent/HK1198921A1/xx unknown
-
2017
- 2017-11-10 JP JP2017217054A patent/JP2018065818A/ja active Pending
-
2019
- 2019-09-27 JP JP2019176350A patent/JP2020023513A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015504921A5 (ja) | ||
| RU2014134720A (ru) | Противомикробные композиции, содержащие dgla, 15-онера и/или 15-hetre, и способы их применения | |
| EP2328573B1 (en) | Antibacterial combination therapy for the treatment of gram positive bacterial infections | |
| CR20200148A (es) | Compuestos monobactámicos cromados para el tratamiento de infecciones bacterianas | |
| JP2012522037A5 (ja) | ||
| JP2013253094A5 (ja) | ||
| RU2010140682A (ru) | Способ лечения пациента от инфекции, фармацевтическая композиция (варианты) и лекарственное средство | |
| JP2008520660A5 (ja) | ||
| WO2012017349A3 (en) | Topical pharmaceutical composition comprising nanonized silver sulfadiazine and chlorhexidine gluconate | |
| EP3829299A1 (en) | Bismuth-thiol compositions and methods for treating wounds | |
| Morata et al. | New antibiotics against gram-positives: present and future indications | |
| JP2016507547A5 (ja) | ||
| RU2015132369A (ru) | Комбинированная терапия для лечения нозокомиальной пневмонии | |
| JP2018500387A5 (ja) | ||
| Elston | Topical antibiotics in dermatology: emerging patterns of resistance | |
| Gunjan et al. | A comparative study of the effect of different topical agents on burn wound infections | |
| JP2013510861A5 (ja) | ||
| JP2020536966A5 (ja) | ||
| NZ706734A (en) | Pharmaceutical compositions useful for the treatment or control of bacterial infections | |
| JP5276653B2 (ja) | カルバペネム類を含む殺菌性抗ｍｒｓａ活性医薬組成物 | |
| JP2024009968A5 (ja) | ||
| JP2018521143A5 (ja) | ||
| WO2015112977A1 (en) | Antimicrobial formulations and applications thereof | |
| JP6525999B2 (ja) | 抗菌性組成物 | |
| JP2015524461A5 (ja) |